Early Development Biostatistics, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Clin Pharmacol Ther. 2018 Jul;104(1):72-80. doi: 10.1002/cpt.1036. Epub 2018 Feb 23.
Digital therapeutics represent a new treatment modality in which digital systems such as smartphone apps are used as regulatory-approved, prescribed therapeutic interventions to treat medical conditions. In this article we provide a critical overview of the rationale for investing in such novel modalities, including the unmet medical needs addressed by digital therapeutics and the potential for reducing current costs of medical care. We also discuss emerging pathways to regulatory approval and how innovative business models are enabling further growth in the development of digital therapeutics. We conclude by providing some recent examples of digital therapeutics that have gained regulatory approval and highlight opportunities for the near future.
数字疗法是一种新的治疗方式,其中数字系统(如智能手机应用程序)被用作监管部门批准的、规定的治疗干预措施,以治疗医疗状况。在本文中,我们对投资这种新型模式的基本原理进行了批判性的概述,包括数字疗法所解决的未满足的医疗需求以及降低当前医疗成本的潜力。我们还讨论了新兴的监管审批途径,以及创新的商业模式如何促进数字疗法的进一步发展。最后,我们提供了一些最近获得监管批准的数字疗法的实例,并强调了不久的将来的机会。